Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant

NCT03961919 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndromes
Transplant-Related Hematologic Malignancy

Interventions

DRUG: Fludarabine
DRUG: ARA-C
DRUG: Treosulfan
PROCEDURE: Peripheral Blood Stem Cell Transplant

Sponsor

Ciceri Fabio